Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study).

MLA

Behrens, Frank, et al. “Rituximab plus Leflunomide in Rheumatoid Arthritis: A Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA Study).” Rheumatology, vol. 60, no. 11, Nov. 2021, pp. 5318–28. EBSCOhost, https://doi.org/10.1093/rheumatology/keab153.

APA

Behrens, F., Koehm, M., Rossmanith, T., Alten, R., Aringer, M., Backhaus, M., Burmester, G. R., Feist, E., Herrmann, E., Kellner, H., Krueger, K., Lehn, A., Müller-Ladner, U., Rubbert-Roth, A., Tony, H.-P., Wassenberg, S., & Burkhardt, H. (2021). Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). Rheumatology, 60(11), 5318–5328. https://doi.org/10.1093/rheumatology/keab153

Chicago

Behrens, Frank, Michaela Koehm, Tanja Rossmanith, Rieke Alten, Martin Aringer, Marina Backhaus, Gerd R Burmester, et al. 2021. “Rituximab plus Leflunomide in Rheumatoid Arthritis: A Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA Study).” Rheumatology 60 (11): 5318–28. doi:10.1093/rheumatology/keab153.